ZPDH:XETRA:XETRA-SPDR S&P U.S. Health Care Select Sector UCITS (EUR)

ETF | Others |

Last Closing

USD 36.34

Change

-0.23 (-0.62)%

Market Cap

N/A

Volume

4.96K

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-05-07 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
JARI:XETRA Amundi Index Solutions - Amund..

-0.28 (-0.61%)

USD 100.65B
EUNL:XETRA iShares Core MSCI World UCITS ..

-0.45 (-0.48%)

USD 84.07B
FRCJ:XETRA UBS MSCI Japan Socially Respon..

-0.09 (-0.38%)

USD 79.79B
AW15:XETRA UBS (Irl) ETF plc - MSCI Japan..

-0.19 (-1.45%)

USD 58.88B
FJPR:XETRA Fidelity Sustainable Research ..

-0.01 (-0.23%)

USD 44.90B
EXX7:XETRA iShares Nikkei 225 UCITS ETF (..

-0.19 (-0.83%)

USD 28.25B
SPYL:XETRA SPDR S&P 500 UCITS ETF USD Acc..

-0.05 (-0.44%)

USD 23.49B
PPFB:XETRA iShares Physical Gold ETC EUR

-0.19 (-0.32%)

USD 20.66B
XDEE:XETRA Xtrackers S&P 500 Equal Weight..

-0.01 (-0.05%)

USD 12.74B
EUN5:XETRA iShares Core Corporate Bond UC..

+0.25 (+0.21%)

USD 12.26B

ETFs Containing ZPDH:XETRA

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -9.74% 22% F 23% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -9.74% 25% F 25% F
Trailing 12 Months  
Capital Gain -8.90% 13% F 19% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -8.90% 16% F 21% F
Trailing 5 Years  
Capital Gain 38.04% 46% F 49% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 38.04% 47% F 48% F
Average Annual (5 Year Horizon)  
Capital Gain 11.87% 74% C 73% C
Dividend Return 11.87% 73% C 71% C-
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 10.93% 57% F 65% D
Risk Adjusted Return 108.55% 93% A 94% A
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

What to not like:

There is nothing we particularly dislike